Form 4: Cingulate Inc. Executive Matthew Brams Reports Stock Option Grant
SEC Form 4 Filing
EVP and Chief Medical Officer of Cingulate Inc., Matthew Brams, reports the acquisition of stock options.
Summary
- Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., filed a Form 4 on February 20, 2025, reporting a transaction.
- On February 18, 2025, Brams acquired 17,630 stock options with an exercise price of $4.32.
- These options vest 25% on the one-year anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following 36 months.
- The options expire on February 18, 2035.
- Following the reported transaction, Brams directly owns 17,630 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders, potentially incentivizing performance.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of stock option grant and transaction. |
| 02/20/2025 | Date of Form 4 filing. |
| 02/18/2035 | Expiration date of the stock options. |
Keywords
Form 4, Stock Options, Cingulate Inc., Matthew Brams, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.